Previous close | 11.83 |
Open | 11.81 |
Bid | 11.90 x 3200 |
Ask | 11.94 x 6400 |
Day's range | 11.77 - 12.02 |
52-week range | 8.74 - 13.62 |
Volume | |
Avg. volume | 10,201,652 |
Market cap | 14.18B |
Beta (5Y monthly) | 1.14 |
PE ratio (TTM) | 238.80 |
EPS (TTM) | 0.05 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | 0.48 (4.06%) |
Ex-dividend date | 08 Mar 2024 |
1y target est | 15.00 |
At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of building a more durable, higher-margin portfolio of patented innovation on the foundation of its strong base business. The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday. The companies were reviewing the content of the health regulator's so called complete response letter (CRL) and would soon determine the appropriate next steps, they said, without disclosing further details. Mapi Pharma did not immediately respond to Reuters requests for additional details on the contents of the CRL, which indicates that an application would not be approved in its present form and requires more information.
Viatris Inc (NASDAQ:VTRS) recently announced a dividend of $0.12 per share, payable on 2024-03-18, with the ex-dividend date set for 2024-03-08. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's delve into Viatris Inc's dividend performance and assess its sustainability.